NFKB1 and neoplasm: Tumor-derived IL-1β and constitutive IL-1 receptor-associated kinase 4 (IRAK4) activate the NF-κB signaling pathway in CAFs and pancreatic cancer cells, thereby attenuating the sensitivity to gemcitabine (Zhang et al., 2018).